Dexmedetomidine hydrochloride

Pricing Availability   Qty
Description: Potent, highly selective α2 agonist. Active isomer of medetomidine (Cat. No. 5160)
Alternative Names: d-Medetomidine hydrochloride
Chemical Name: 4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole hydrochloride
Purity: ≥98%
Citations (7)
Literature (2)

Biological Activity for Dexmedetomidine hydrochloride

Dexmedetomidine hydrochloride is an active isomer of medetomidine, a potent, highly selective α2-adrenoceptor agonist (Ki values are 1.08 and 1750 nM for α2- and α1-adrenoceptors respectively). Displays greater selectivity over α1-adrenoceptors than Clonidine (Cat. No. 0690) and UK 14,304 (1620-, 220- and 300-fold respectively). Active in vivo; displays hypotensive, bradycardic, sedative, anxiolytic, hypothermic and analgesic effects.

Racemate also available.

Compound Libraries for Dexmedetomidine hydrochloride

Dexmedetomidine hydrochloride is also offered as part of the Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.

Technical Data for Dexmedetomidine hydrochloride

M. Wt 236.74
Formula C13H16N2.HCl
Storage Desiccate at RT
Purity ≥98%
CAS Number 145108-58-3
PubChem ID 6918081
Smiles C[C@H](C2=CN=CN2)C1=C(C)C(C)=CC=C1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Dexmedetomidine hydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
water 23.67 100
DMSO 23.67 100

Preparing Stock Solutions for Dexmedetomidine hydrochloride

The following data is based on the product molecular weight 236.74. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 4.22 mL 21.12 mL 42.24 mL
5 mM 0.84 mL 4.22 mL 8.45 mL
10 mM 0.42 mL 2.11 mL 4.22 mL
50 mM 0.08 mL 0.42 mL 0.84 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for Dexmedetomidine hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for Dexmedetomidine hydrochloride

References are publications that support the biological activity of the product.

Virtanen et al (1988) Characterization of the selectivity, specificity and potency of medetomidine as an α2-adrenoceptor agonist. Eur.J.Pharmacol. 150 9 PMID: 2900154

Fisher et al (1991) Antinociceptive properties of intrathecal dexmedetom. in rats. Eur.J.Pharmacol. 192 221 PMID: 1674472

Scheinin et al (1989) Medetomidine - a novel α2-adrenoceptor agonist: a review of its pharmacodynamic effects. Prog.Neuro-Psychopharm.Biol.Psychiat. 13 635 PMID: 2571177

If you know of a relevant reference for Dexmedetomidine hydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Adrenergic α2 Receptor Agonists

Keywords: Dexmedetomidine hydrochloride, Dexmedetomidine hydrochloride supplier, Active, isomer, α2-Adrenergic, alpha2-Adrenergic, Receptors, α2-adrenoceptor, alpha2-adrenoceptors, a2-adrenoceptors, a2-adrenergic, d-Medetomidine, hydrochloride, Adrenergic, Alpha-2, 2749, Tocris Bioscience

7 Citations for Dexmedetomidine hydrochloride

Citations are publications that use Tocris products. Selected citations for Dexmedetomidine hydrochloride include:

Garrity et al (2015) Dexmedetomidine-induced sedation does not mimic the neurobehavioral phenotypes of sleep in Sprague Dawley rat. Invest Ophthalmol Vis Sci 38 73 PMID: 25325438

McAlvin et al (2015) Corneal Anesthesia With Site 1 Sodium Channel Blockers and dexmedetom. J Inflamm (Lond) 56 3820 PMID: 26066750

Yuki et al (2011) Sedative drug modulates T-cell and lymphocyte function-associated antigen-1 function. Anesth Analg 112 830 PMID: 21385989

Uchida et al (2019) Induction of Non-Apoptotic Cell Death by Adrenergic Agonists in Human Oral Squamous Cell Carcinoma Cell Lines. Anticancer Res 39 3519 PMID: 31262876

Do you know of a great paper that uses Dexmedetomidine hydrochloride from Tocris? Please let us know.

Reviews for Dexmedetomidine hydrochloride

There are currently no reviews for this product. Be the first to review Dexmedetomidine hydrochloride and earn rewards!

Have you used Dexmedetomidine hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.